Rubin, David T.
Sandborn, William J.
Bosworth, Brian
Zakko, Salam
Gordon, Glenn L.
Sale, Mark E.
Rolleri, Robert L.
Golden, Pamela L.
Barrett, Andrew C.
Bortey, Enoch
Forbes, William P.
Funding for this research was provided by:
Salix Pharmaceuticals, Inc.
Article History
Received: 27 April 2015
Accepted: 3 September 2015
First Online: 19 September 2015
Compliance with ethical standards
:
: David Rubin has received grant/research support and/or has served as a consultant for AbbVie, Emmi Solutions, Genentech, Janssen Pharmaceuticals, Inc., Prometheus Laboratories, Inc., Santarus, Inc. (previously a wholly owned subsidiary of Salix, a Division of Valeant Pharmaceuticals North America LLC), Shire, Takeda Pharmaceutical Co., Ltd., Telsar Pharma, Inc., UCB Pharma, and Warner Chilcott; and is a co-founder of the nonprofit medication education entity Cornerstones Health, Inc. William Sandborn has served as a consultant for AbbVie, ActoGeniX NV, AGI Therapeutics, plc, Alba Therapeutics Corp., Albireo, Alfa Wassermann, AM-Pharma BV, Amgen, Anaphore, Aptalis, Astellas, Athersys, Inc., Atlantic Healthcare plc., BioBalance Corp., Boehringer-Ingelheim, Bristol-Myers Squibb, Celek Pharmaceuticals, Celgene, Cellerix SA, Cerimon Pharmaceuticals, ChemoCentryx, CoMentis, Coronado Biosciences, Cosmo Technologies Ltd., Cytokine Pharmasciences, Eagle Pharmaceuticals, Eisai Medical Research Inc., Elan Pharmaceuticals, Eli Lilly, EnGene, Inc., Enteromedics, Exagen Diagnostics, Inc., Ferring Pharmaceuticals, Flexion Therapeutics, Inc., Funxional Therapeutics Limited, Genentech, Genzyme Corp., Gilead Sciences, Given Imaging, GlaxoSmithKline, Human Genome Sciences, Ironwood Pharmaceuticals, Janssen, KaloBios Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Lycera Corporation, Meda Pharmaceuticals, Merck & Co., Merck Research Laboratories, MerckSerono, Millennium Pharmaceuticals, Nisshin Kyorin Pharmaceutical Co., Ltd., Novo Nordisk A/S, NPS Pharmaceuticals, Optimer Pharmaceuticals, Orexigen Therapeutics, Inc., PDL BioPharma, Pfizer, Procter and Gamble, Prometheus Laboratories, ProtAb Ltd., Purgenesis Technologies, Inc., Receptos, Relypsa, Inc., S.L.A. Pharma (UK) Ltd., Salient Pharmaceuticals, Salix, Santarus, Inc., Shire, Sigmoid Pharma Ltd., Sirtris Pharmaceuticals, Inc., Targacept, Teva Pharmaceutical Industries, Ltd., Therakos, Tillotts Pharma AG, TxCell SA, UCB, Vascular Biogenics Ltd., Viamet Pharmaceuticals, and Warner Chilcott UK Ltd.; he has received speakers’ bureau fees for AbbVie, Bristol-Myers Squibb, and Janssen; and he has received financial support for research from AbbVie, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Janssen, Millennium Pharmaceuticals, Novartis, Pfizer, Procter and Gamble, Shire, and UCB. Brian Bosworth is a consultant, is on the speakers’ bureau for, and has received research grants from Salix. Salam Zakko serves as principal investigator on a variety of research protocols for, receives unrestricted grants from, and serves on the speakers’ bureau for Salix. Glenn Gordon is a consultant, is on the speakers’ bureau, and has received research grants from Salix; serves as a consultant to and is on the speakers’ bureau for AbbVie, Aptalis, Janssen, Prometheus Laboratories, sanofi-aventis US LLC, Takeda Pharmaceutical Co., Ltd., UCB, and Warner Chilcott UK Ltd.; has received research grants from AbbVie, Aptalis, Avaxia Biologics, Inc., Coronado Biosciences, Cubist Pharmaceuticals, Dr. Falk Pharma GmbH, Evoke Pharma, Ferring Pharmaceuticals, Furiex Pharmaceuticals, GlaxoSmithKline, Hutchinson MediPharma Ltd., Janssen, Lexicon Pharmaceuticals, Pfizer Inc., Prometheus Laboratories, Red Hill BioPharma Ltd., Revogenex Inc., sanofi-aventis U.S. LLC, Shire, Takeda Pharmaceutical Co., Ltd., Theravance, Tranzyme, United Biosource Corporation, UCB, Ventrus Biosciences, and Warner Chilcott UK Ltd. Mark Sale is a consultant for Salix. Robert Rolleri, Pamela Golden, Andrew Barrett, Enoch Bortey, and William Forbes are former employees of Salix.